The majority of non-pilocytic astrocytomas (PAs) are associated with mutations in MAPK pathway activation [174], which can induce cancer gene aging, and have been observed in 90% of PA samples with enhanced beta-galactose-glucoside enzyme activity and increased p16 INK4a expression [175]. The gene discussed is CDKN2A; the disease is cancer.